Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma
C. Chattopadhyay, J. Roszik, R. Bhattacharya, M. Alauddin, I. Mahmud, S. Yadugiri, M. M. Ali, F. S. Khan, V. V. Prabhu, P. Lorenzi, E. Burton, R. R. Morey, R. Lazcano, M. A. Davies, S. P. Patel, E. A. Grimm
Abstract
PurposeUveal melanoma (UM) is a highly aggressive disease with very few treatment options. We previously demonstrated that mUM is characterized by high oxidative phosphorylation (OXPHOS). Here we tested the anti-tumor, signaling and metabolic effects of imipridones, CLPP activators which reduce OXPHOS indirectly and have demonstrated safety in patients. Experimental DesignWe assessed CLPP expression in UM patient samples. We tested the effects of imipridones (ONC201, ONC212) on the growth, survival, signaling and metabolism of UM cell lines in vitro, and for therapeutic effects in vivo in UM liver metastasis models. ResultsCLPP expression was confirmed in primary and mUM patient samples. ONC201/212 treatment of UM cell lines in vitro decreased OXPHOS effectors, inhibited cell growth and migration, and induced apoptosis. ONC212 increased metabolic stress and apoptotic pathways, inhibited amino acid metabolism, and induced cell death-related lipids. ONC212 also decreased tumor burden and increased survival in vivo in two UM liver metastasis models. ConclusionImipridones are a promising strategy for further testing and development in mUM.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth.
C. Chattopadhyay, R. Bhattacharya, … E. A. Grimm·bioRxiv·Oct 26, 2022
- Patient-derived zebrafish xenograft models reveal ferroptosis as a fatal and druggable weakness in metastatic uveal melanoma
A. Groenewoud, J. Yin, … E. Snaar-Jagalska·bioRxiv·Oct 26, 2021
- Inhibition of Metastatic Uveal Melanoma Cell Proliferation by the Histone Deacetylase 6 Inhibitor, Ricolinostat, is Linked to Altered Microphthalmia-associated Transcription Factor and Phospho-ERK Expression
H. Sundaramurthi, S. Garcia-Mulero, … B. N. Kennedy·bioRxiv·Oct 28, 2021
- High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
K. Slater, A. B. Heeran, … B. N. Kennedy·bioRxiv·Aug 23, 2020
- Comparative phosphoproteome analysis of primary and metastatic uveal melanoma cell lines
K. Glinkina, R. G. Prieto, … A. G. Jochemsen·bioRxiv·Dec 6, 2023
- Atovaquone-induced therapeutic rewiring of melanoma metabolism
Mayra A. Betancourt Ponce, Alexa R. Heaton, … Lisa Marie Barroilhet·Journal of Investigative DermatologyPeer-reviewed·Mar 24, 2026